Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

PSMA PET/CT-targeted biopsy improves detection of clinically significant prostate cancer

PSMA PET/CT-targeted biopsy detects more clinically significant prostate cancer than systematic biopsy alone in men with negative or inconclusive MRI findings but persistent clinical risk factors. According to new research published in The Journal of Nuclear Medicine, combining the two biopsy approaches is even more effective, nearly doubling the detection rate. This strategy may help physicians…

PSMA PET/CT-targeted biopsy improves detection of clinically significant prostate cancer

We haven't written up this one. Medical Xpress has the full story — the link below goes straight to it.

Read the original at medicalxpress.com →

More in Health & Medicine

Shionogi Grows Rare Disease Portfolio with $2B IntraBio Acquisition

Shionogi signaled its intent to focus on rare disease drugs in April when it acquired Radicava (edaravone), an amyotrophic lateral sclerosis (ALS) treatment, from Tanabe Pharma for $2.5 billion and…

  • Shionogi acquires IntraBio for $2 billion to expand rare disease portfolio.
  • Aqneursa, FDA-approved in September 2024, treats NPC and ataxia.
  • Deal subject to closing conditions, follows Radicava acquisition in April.

More from Tuesday 6 October →